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ABSTRACT 
In order to generate further characterisation data for the lyophilised product Erwinia 
chrysanthemi L-asparaginase, reconstituted drug product (DP, marketed as Erwinase 
or Erwinaze) was analysed for sub-visible (2-10µm) particulate content using both the 
Light Obscuration (LO) method and the newer Flow-Imaging Microscopy (FIM) 
technique. There was no correlation of sub-visible particulate counts between FIM 
and LO, nor do the counts correlate with activity at both release and on stability. The 
sub-visible particulate content of lyophilised Erwinia L-asparaginase appears to be 
consistent and stable over time and in line with other parenteral biopharmaceutical 
products. The majority (ca. 75%) of sub-visible particulates in L-asparaginase DP 
were at the low end of the measurement range by FIM (2 - 4 µm). In this size range, 
FIM was unable to definitively classify the particulates as either protein or non- 
protein. More sensitive measurement techniques would be needed to classify the 
particulates in lyophilised L-asparaginase into type (protein and non-protein), so the 
LO technique has been chosen for on-going DP analyses. Erwinia chrysanthemi L- 
asparaginase has a lower rate of hypersensitivity compared with native Escherichia 
coli preparations, but a subset of patients develop hypersensitivity to the Erwinia 
enzyme. A DP lot that had sub-visible particulate counts on the upper end of the 
measurement range by both LO and FIM had the same incidence of allergic 
hypersensitivity in clinical experience as lots at all levels of observed sub-visible 
particulate content, suggesting that the presence of L-asparaginase sub-visible 
particulates is not important with respect to allergic response. 
Keywords :  L-asparaginase; sub-visible particulates; Erwinia; light obscuration; flow- 
imaging microscopy 
 
 
1.0 Introduction 
 
L-asparaginase or L-asparagine amidohydrolase (EC 3.5.1.1) is an enzyme that catalyses 
the conversion of L-asparagine (L-Asn) to L-aspartic acid (L-Asp), with the evolution of 
ammonia. The enzyme is routinely used in chemotherapy regimens for the treatment of 
acute lymphoblastic leukaemia (ALL) (1). In this chemotherapeutic setting, the enzyme is 
used to decrease the serological concentration of L-Asn, thus depriving leukaemic cells of 
an essential amino acid nutrient (2). Clinical preparations of the enzyme are derived from 
two bacteria: Escherichia coli L-asparaginase (EcA) and Erwinia chrysanthemi L- 
asparaginase (ErA). In most instances, ErA is used in patients who  develop 
hypersensitivity to EcA (3,4). As for all parenteral products, the measurement of sub- 
visible particulates (SbVP) is an important consideration for manufacture and clinical 
supply of both ErA and EcA. ErA drug product (DP) is supplied as lyophilized protein for 
administration after reconstitution. 
The formation of protein aggregates in a biopharmaceutical product must be controlled and 
understood, and is an important process to consider when designing drug product (DP) 
formulations. Protein aggregates may take the form of usually smaller, soluble aggregates 
or larger, insoluble aggregates including SbVP (5). Lyophilisation, as a process which 
removes water from the protein matrix and therefore brings protein molecules into closer 
proximity, must be regarded as a potential aggregation-inducing step (6) requiring further 
analysis with respect to SbVP. Multi-subunit proteins, such as the tetrameric 140kDa 
(35kDa subunit) L-asparaginase, may also face issues during lyophilisation such as loss of 
quaternary structure and possible loss of activity (7, 8). The degree to which aggregation 
may occur in reconstituted lyophilized DP formulations varies from protein to protein, and 
the degree of aggregation may be reduced or lowered by additions of excipients such as 
sucrose or trehalose (9, 10). 
Concern with regard to the potential for undesired immunogenic reactions from SbVP in 
parenteral products (11) has led to further study in this area in the past few years. Of 
particular interest is the size range between 2 and 10µm; however the measurement of 
SbVP in this range is a technically challenging and evolving area for both regulators and 
industry (11, 12). Normally for routine quality-control testing of biologic products, the 
light obscuration (LO) technique is applied, but this is thought to be non-ideal in the 2 - 
10µm range for biologic products with translucent protein SbVPs (13, 14). A newer 
technique for measurement of SbVP is flow-imaging microscopy (FIM) which has the 
capability to classify particulate matter as well as provide size distributions and particulate 
counts (15, 16). Using FIM, algorithms can be produced in order to classify particles 
based on image characteristics such as shape or translucency (17, 18). 
Recently, the ErA manufacturing process has been subject to a number of process 
validation and process robustness studies (19, 20) to meet regulatory requirements as well 
as in order to increase process understanding. As a process understanding measure, SbVP 
in ErA DP manufacturing and stability settings are routinely analysed using the LO 
technique. As part of our on-going process understanding efforts around  the 
manufacturing process for ErA, SbVP have also been measured using the FIM technique. 
In this paper, we compare LO data to FIM measurements for ErA DP. In addition, we 
compare the SbVP data to the clinical experience for a subset of DP lots. 
2.0 Materials and Methods 
 
Reagents used were obtained from Sigma (Gillingham, Dorset, UK) unless otherwise 
indicated. Lyophilised DP vials of Erwinia chrysanthemi L-asparaginase (Erwinase®, 
Porton Down, UK) were obtained from full-scale manufacturing stocks (Public Health 
England, Porton Down, UK). 
Light obscuration. The LO measurements were conducted using a Particle Measuring 
Systems (Boulder, CO, USA) APSS-200 instrument at Reading Scientific Services 
Limited (RSSL, Reading, UK) according to the United States Pharmacopeia (USP) 
monograph number 788, adapted for 2 – 10µm size range assessments (21). DP samples 
were reconstituted in 1 – 2mL per vial using 0.9% sterile saline per the clinical product 
leaflet instructions for ErA. According to the approved and licensed release method used 
for ErA DP, reconstituted samples were pooled (approximately 20 vials) in order to 
provide enough sample for LO analysis. 
Flow-imaging microscopy. A Fluid Imaging Technologies FlowCAM VS-I (Yarmouth, 
Maine, USA) with an FC80-7FV flow cell (80µm depth of field, 700µm width), and 10X 
objective, was used for FIM analyses. The Visual Spreadsheet analysis software was used 
for data processing, and the software settings are provided in Table 1. The vials were 
reconstituted in 1.5mL 0.9% sterile saline (Oxoid Limited, Basingstoke, UK) with gentle 
swirling agitation and no stopper contact, per the clinical product leaflet instructions for 
ErA. Samples were reconstituted immediately prior to FIM analysis, unless otherwise 
indicated in the text. For each analysis, the FlowCAM was primed with the sample, and 
the analyses were conducted on 250µL throughput volumes. Analyses of blank vials 
(protein and excipient-free) were conducted as for the DP analysis; 1.5mL 0.9% sterile 
saline was added to a glass vial and used in the FIM analysis. Each analysis took 
approximately 5 minutes to conduct.  Particle size data were calculated using Equivalent 
Spherical Diameter (ESD), which is calculated using the mean of 36 independent 
measurements of Feret diameter. 
Size-exclusion chromatography. The size-exclusion chromatography (SEC) analyses were 
conducted using a TSKgel G3000SWXL column (Tosoh Bioscience GmbH, Stuttgart, 
Germany) and a Waters HPLC workstation (Elstree, UK). The running  buffer  was 
100mM sodium phosphate at pH7.2 with 100mM NaCl and the column eluate was 
monitored using a variable-wavelength UV detector at 220nm. 
L-Asparaginase Activity. The L-asparaginase activity assay was conducted using a 
method based on the Berthelot reaction and methods described in the literature (22, 23). 
 
 
 
3.0 Results and Discussion 
 
ErA is presented as a lyophilized dosage form with a high degree of stability under the 
recommended storage conditions of 2 – 8°C. Throughout the manufacturing process and 
prior to aseptic lyophilisation (19), the product is filtered several times using 0.22µm 
sterilizing-grade or sterile filters, in order to comply with the stringent quality 
requirements necessary for parenteral pharmaceutical products. The DP is stored as a 
lyophilized solid and reconstituted with saline solution prior to administration (or analysis 
in the case of these studies). Data for enzyme activity, 2 – 10µm SbVP content as 
measured by the LO method, and soluble aggregates as measured by SEC (Figure 1) 
demonstrate the robust stability of the product over the 36-month shelf life. In particular, 
one notes that protein aggregate content, for both soluble aggregates (SEC) and insoluble 
aggregates (LO), does not appreciably change or increase over the shelf life of the product. 
Furthermore, an assessment of soluble aggregates versus insoluble aggregates (SEC and 
LO data) was made, but there was no correlation between the two data sets (data not 
shown). 
Prior to engaging in detailed analysis of SbVP using FIM, the method was defined and 
qualified during an assay development phase. The final software parameters used with the 
FIM instrument (Table 1) were defined and qualified to ensure reproducibility of results. 
A population of ten vials from one ErA lot was analysed, with each vial being analysed in 
four repeats, for a total of 40 analyses (Figure 2). This strategy allowed both the intra-vial 
and inter-vial variability to be assessed. The counts in the 2 – 10µm Equivalent Spherical 
Diameter (ESD) particle range show the intra-vial variability, based on four 250µL 
aliquots analysed from the same reconstituted vial, to be low, with nine out of ten vials 
having a percentage coefficient of variance (%CV) ≤6%, and eight out of ten vials with a 
%CV of ≤2.5%. The low intra-vial variance suggests that FIM measurements are very 
reproducible given a consistent analyte.  It is important to note that at this early stage, the 
%CV as a parameter may not have meaning in absolute terms, therefore it is only provided 
as a measure of variance relative to the other data in this set. The inter-vial %CV in this 
data set was much higher at 38.8%, over 10 observations. One potential reason for the 
inter-vial variability observed using FIM is the fact that Erwinase DP is presented as a 
lyophilized product and that reconstitution of the DP prior to analysis may introduce an 
inherent variability in the particulate counts from vial to vial compared with other 
commercial liquid protein formulations. Such variability in SbVP content is not detectable 
using the pharmacopoeial ErA LO method, as tens of vials are required for pooling to 
generate one data point using this technique. 
Theoretically, the vial-to-vial variability in FIM results may be due to presence of air 
bubbles or other causes introduced during sample preparation. In this study, DP samples 
were   reconstituted   according   to   the   approved   clinical   instructions   for   Erwinase 
administration, so as to provide an accurate representation of the material that the patient 
receives. It is important to note that during this study, special care was taken to conduct 
the reconstitution procedure in a consistent way. However, the variability in the vial-to- 
vial FIM measurements is not believed to be due to sample handling or the presence of air 
bubbles, based on analyses of blank vials consisting of 0.9% saline without the presence of 
protein. These analyses (Figure 3) indicate that any matrix-based or sample-handling 
based variability is not responsible for the overall variance of ErA FIM measurements, as 
the background particle counts are nearly two orders of magnitude less than the typical 
ErA counts. While some background contribution to the particle counts is evident, it is too 
low to account for the variance observed in the ErA DP vial-to-vial measurements. It is 
worth noting, however, that these measurements of background particulate counts were 
made using diluent in the absence of protein. It is possible that other effects due to 
solution properties (including matrix viscosity or the presence of protein) may have also 
played a role in microbubble formation and therefore contributed to the vial-to-vial 
variance. 
Interestingly, the contribution to the particulate count background, though likely very low 
compared to the protein contribution, appeared to be mainly from the 0.9% saline solution, 
the approved clinical diluent used for ErA DP administration. FIM analyses of 18.2MΩ 
water resulted in counts in the region of 100 particles/mL, which is more than one order of 
magnitude lower than the saline-blank counts. Degassing of the blank solutions was also 
evaluated, but was not found to substantially change the measured levels of background 
particles in the 0.9% saline diluents (data not shown). Furthermore, incubation of 0.9% 
saline over 30min (measured by FIM every 5 minutes) did not have an effect on the 
background particulate counts by FIM (data not shown). Compared with water, saline 
solutions are known to have lower oxygen solubility (24, 25), so it is possible that the 
background particulate counts observed are due to microbubbles formed during natural 
degassing on opening the diluent vials, and this may help explain why further degassing 
had no effect. Based on these results, it is reasonable to conclude that the vial-to-vial FIM 
variability observed is a result of either true intra-lot, vial-to-vial differences in particulate 
load or a result of subtle differences in the reconstitution procedure. 
With these contributions from the matrix background qualified, the inter-lot variability 
(Figure 4) was assessed using eleven lots of ErA DP. The DP lots consisted of real-time 
stability samples held under normal storage conditions (2 – 8ºC), including DP at the start 
and end of shelf-life (36 months), as well as beyond end of shelf-life (43 months). A 
number of vials were reconstituted and analysed per batch to provide  representative 
results, and the data obtained show good consistency from batch to batch. Furthermore, 
the absolute values for SbVP particulate counts are in line with the particulate contents 
reported for other protein formulations using FIM (26). 
The FIM data from Figure 4 were plotted against the corresponding LO data to evaluate 
whether there was a correlation between the two techniques in the 2 – 10µm size range 
(Figure 5). Each FIM data point in the figure represents the mean value for between 6 
and 20 individual vials analysed. As expected based on literature reports (12), the FIM 
particulate counts are higher than those for the LO technique. Although the FIM 2 – 
10µm particulate counts cover a range (193,000 – 493,000 particles/vial) there appears to 
be no correlation with the LO data (14,698 and 50,356 particles/vial). Ideally, one might 
expect a linear relationship between the two methods; however in measurements of ErA 
DP, the two data sets show little agreement with respect to lot identity. The reasons for 
this difference are not understood, but may be in part due to sample handling effects as 
discussed above. One further possibility for the observed variability was a change in the 
particulate content of reconstituted DP over time.  Therefore, a time-course study of ErA 
DP vials was conducted. The vials were held for varying lengths of time between 5 and 
30min prior to FIM analysis, and the data (data not shown) demonstrated that there was no 
change in the 2-10µm particulate count over this time period. 
One of the potential benefits of analysis by FIM is the possibility of classification of 
particulate matter using a range of statistical and image processing tools. During each 
FIM analysis, a large number of images is generated, one image per particle counted. 
These images may be assessed using computer software and various algorithms to attempt 
to separate particulate populations from one another. For instance, circular particulates 
may be more likely to be non-proteinaceous, such as microbubbles, and can be 
characterized separately from proteinaceous particulate matter (26). 
At the most basic level, the FIM technology is able to sub-classify particulate populations 
based on size, down to one-micron intervals or smaller. Applying this principle to the ErA 
data discussed above, it is clear that the vast majority of particulate matter is in the lower 
part of the size range between 2 and 10µm, as shown in Figure 6 for a typical ErA DP 
analysis. In the example analysis shown in the figure, approximately 90% of the particles 
in the 2 - 10µm size range are below 6µm ESD, and approximately 75% are at or below 
4µm ESD. 
The typical particle size distribution for Erwinase DP FIM analyses is an important factor 
to consider when applying further classification filters to the data set. In our experience, 
although FIM is very good at processing large quantities of particulate images, the image 
processing software cannot accurately classify particulate images below 4 or 5µm, and can 
only partially classify particles between 5 and 10µm. The limitation is related to the 
resolution of the FIM microscope and camera, and the degree of pixellation involved in 
images of very small particles. When the particle is very small, the system cannot assign 
enough pixels to the image to physically allow the computer to distinguish between a 
circle and other shapes. Furthermore, small particles (2 - 10µm) may be slightly out-of- 
focus due to the depth of field of the flow cell (80µm), unless they are close to the focal 
point. This is a difficult technical problem with the currently-available FIM instruments. 
A smaller flow cell might address this problem but could be liable to blockages from 
larger particulates (ca. >40µm). Such a flow cell was not available at the time this work 
was conducted. 
Therefore, further classification of ErA FIM data is not straightforward. In a typical ErA 
DP analysis, approximately 75% of the total particulates in the size range of interest (2 - 
10µm) are outside the capabilities of the software to adequately determine shape, and the 
remaining 25% of the population are extremely challenging to classify (Figure 7). The 
first particle (top left) in the figure is highly likely to be non-protein in nature but cannot 
be further defined. A comparison of this image with the images of 2µm particulates as 
well as some of the larger particulate images shows that even those particles which have a 
high degree of circularity and appear quite like the first image cannot be definitively 
classified as non-proteinaceous in nature. 
Despite these challenges, attempts were made to classify 2-10µm particulates in 
reconstituted ErA DP vials using FIM statistical filters. In order to illustrate, a single vial 
of ErA DP was analysed and first a filter was applied to identify the images which were 
non-protein in nature.  Statistical filters for the circularity (0.9 – 1.0) and compactness (1.0 
– 1.4) were applied, with the values based on standard libraries of images of air bubbles 
and round sub-visible particulate matter. The filters were only able to identify 9% of the 
images in the 2 – 10µm size range using these two filters (4,146 particle images out of 
47,931 total). A quick review of the images in the remaining 91% (and therefore not 
identified as circular) identified a substantial number of images which appeared to be non- 
proteinaceous.  Further statistical filters to classify these remaining particles were applied, 
including those for aspect ratio and intensity as used by other researchers (16), but these 
did not provide an absolute differentiation of images either, with clear examples of missed 
non-protein and/or protein particles in the wrong classification sets (data not shown). Fine- 
tuning the analysis to different aspect ratio or intensity ranges did not yield substantially 
different results. 
However, from this particle classification exercise, a few points become apparent. First, 
the size analysis based on ESD works quite well and this is apparent when comparing the 
overall sizes of the particles in Figure 7. Second, the first filter, designed from statistical 
libraries to find round particles, identified a population of these species, but missed a high 
degree of particles also likely non-proteinaceous. A large proportion of the missed 
particles were in the smaller end of the size range, and as expected, the instrumentation 
struggled to classify images at the smallest sizes. When compared with the smaller 
particles, the images in this last 5 – 10µm size range are better and easier to visually 
classify in terms of protein and non-protein species, although there are exceptions even at 
this size. The discrepancy in selection of particles may be due to the background of the 
microscopic field, the binary overlay applied to each FIM image by the software, or other 
factors not fully understood. 
Although obtaining an accurate classification of 2 - 10µm particulate species in ErA DP 
has proven to be difficult, it is clear that protein and non-protein particulates are present. 
The vast majority of the particles lie at the lower end of the subvisible range, where the 
resolution of the instrument and the software are impaired, making it very difficult if not 
impossible to obtain an accurate classification. The higher particle range (>5µm) 
represents a small fraction of the total subvisible particle count, and is also far from 
straightforward to accurately classify.   A more powerful flow microscope, with better 
resolution in the 2 – 5µm size range, would be advantageous at solving this technical 
issue. 
The presence of proteinaceous SbVP in ErA DP, although difficult to absolutely quantify, 
could at least be confirmed using the FIM technology. The presence of these protein 
SbVP in ErA is consistent with other biopharmaceutical products as has been described at 
length in the literature (12, 26). As can be observed in Figure 7, the ErA particulate matter 
which is clearly proteinaceous in nature has aspect ratios significantly different to 1:1, and 
have long, string-like morphology or clusters of protein fibrils. These morphologies were 
observed for ErA particulates greater than 5µm, and are particularly apparent for the larger 
particles in the 10 - 25µm size range. It is these large, sub-visible aggregates of protein 
that are potentially of concern with regards to undesired immunogenicity of protein 
products (27). An undesired immunogenic reaction, such as an allergic reaction, to 
administration of ErA could have an effect on product efficacy and possibly patient safety. 
At the time of writing, no prior reports of SbVP data are known for any L-asparaginase 
product including ErA and EcA with or without any link to hypersensitivity events. 
However, in order to increase our product and process knowledge, and understand the 
potential impact of SbVP on immunogenicity of ErA, a retrospective evaluation of reports 
of patient allergic reactions was conducted with respect to SbVP content by LO and 
FIM. Allergic reaction to ErA, which includes both anaphylaxis and hypersensitivity, 
occurs in approximately 17% of patients (28) and only a subset (20 – 30%) of the patients 
who have already had a hypersensitivity reaction to EcA (3, 29). In addition, 
hypersensitivity events from ErA may be less severe than those due to EcA (3). 
In ALL treatment with L-asparaginase (including EcA and ErA), the mechanism of 
allergic reaction is not clear.  The formation of anti-asparaginase antibodies is a common 
occurrence during treatment, but does not necessarily result in allergic reaction or 
hypersensitivity. In one study (30), a significant proportion of patients (36%) treated with 
EcA and ErA developed anti-asparaginase IgG antibodies, but of these, only half of the 
patients had an allergic reaction during treatment. Allergic reactions also occurred in the 
larger patient population that did not develop antibodies, but to a lesser extent (18% of 
patients in the non-antibody group had a reaction versus 56% in the antibody group), and 
development of antibodies did not affect the overall success of the treatment. A separate 
study (31) reported measurable anti-asparaginase antibody formation in both EcA and ErA 
treatment with no difference in the incidence of antibody formation between the two 
preparations, and no allergic reactions were observed in either arm of the study. Anti-ErA 
antibodies were also measured (32) in a further study, with none of the patients 
experiencing hypersensitivity events. A common consequence (in up to 30% of patients) 
of development of anti-asparaginase antibodies is so-called ‘silent inactivation’ (2), in 
which the antibodies confer a degree of resistance to the drug but do not result in other 
clinical symptoms such as allergy. 
In order to help understand if SbVP were involved in allergic reactions to ErA, the data 
from a recently-completed clinical study were evaluated. The clinical trial was a safety 
study in which patients were given ErA at a dosing of 25,000 IU/m2 administered 
intramuscularly 6 times over two weeks (Monday, Wednesday, Friday) to replace each 
single dose of Oncaspar (PEGylated E coli L-asparaginase) remaining on the individual 
patient’s treatment schedule. This difference in dosing between Oncaspar and ErA is 
standard when switching between PEGylated and non-PEGylated L-asparaginases. As 
one dose of Oncaspar was replaced by six doses of ErA, all patients had more than one 
ErA dose, and dosing continued until the end of the individuals treatment protocol, or until 
hypersensitivity occurred. The ErA lot received by each patient was recorded using the 
patient’s Case Report Form (CRF). 
Using clinical data from this trial, we selected a lot of ErA DP that had SbVP counts on 
the upper edge of the historical database by both FIM and LO (the ‘Target Lot’), and 
evaluated it for examination of allergic reaction occurrence versus the wider clinical 
database for four other lots with lower SbVP counts. It is important to note that some 
analyses resulted in high SbVP counts by one technique but low counts by the other; 
therefore the lot selected has high counts by both (48,000 particles/vial by LO, 280,000 
particles/vial by FIM) but does not have the highest counts observed for either technique. 
However, the control group includes lots with some of the lowest counts (14,000 
particles/vial and 20,000 particles/vial for two control lots by LO). Note also that the 
clinical data set in this analysis does not cover all of the lots depicted in Figure 4. A total 
of 1368 patients were enrolled in the clinical study until the point of study termination, 
and of these, 228 were treated with the target lot. 
The rate of allergic reaction reported for patients who received the selected clinical lot 
(Table 2) is approximately the same or lower than that for the wider clinical study. The 
odds ratio for the test lot versus all other lots was 0.58, indicating that the occurrence of 
allergic reaction was as likely (or less likely) to occur with the relatively increased levels 
of SbVP in the target lot. In the ErA (Erwinaze®) product prescribing information (28), 
the overall rate of allergic reaction is reported as 17%, which is higher than (but roughly 
the same order of magnitude as) the incidence found in this work. Although unconfirmed 
for Erwinaze® reactions, allergic reactions are usually immune-system mediated. 
Undesired immunogenicity is a primary concern with regard to levels of SbVP in 
parenteral products, but these clinical data suggest that for ErA, increasing SbVP levels do 
not cause increased incidence of immunogenic reactions or hypersensitivity. 
  
4.1 Conclusions 
 
Like many, if not all protein biopharmaceuticals (regardless of dosage form), the presence 
of sub-visible particulates can be detected in reconstituted ErA DP in the 2 – 10µm size 
range. The particulate counts appear stable over time by both the established LO 
technique and the newer FIM technique, however the vast majority of the particulate 
population was less than or equal to 4µm in size, where FIM could not definitively classify 
particles as proteinaceous. 
Assessment of the potential clinical impact of these protein sub-visible particulates, which 
are widely observed in protein parenteral products, is the main driver for undertaking the 
kind of work described in this paper. Occurrences of hypersensitivity, a type of allergic 
immune response, were found to be approximately the same for an ErA lot with relatively 
high levels of SbVP by both FIM and LO, compared with the overall occurrence in all 
clinical lots; this result suggests that presence of protein SbVPs in ErA clinical 
preparations do not play an important role in triggering allergic reactions. However, each 
protein biopharmaceutical product is different and therefore new protein products must be 
evaluated on a case-by-case basis, to build up a better picture of the relationship between 
protein SbVPs and effects in the clinical setting. 
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Figure 1. Stability data for ErA including SbVP content by LO (A), enzyme activity (B) 
and aggregation state by SEC (C). Each data point represents the mean of measurements 
of four DP lots and the error bars represent ±1SD. 
 
 
 
 
 
Figure 2. Reproducibility of Flow-Imaging Microscopy Analysis of ErA DP. The data 
(counts of 2 – 10µm particles per vial) represent the mean values for four analyses of 
individual reconstituted vials. The intra-vial mean is indicated by each bar, with error bars 
representing ±1SD. The inter-vial mean (over approximately 40 observations of 10 vials) 
mean is also shown. 
  
 
 
Figure 3. Comparison of SbVP Counts in ErA DP and Saline Blanks Using Flow- 
Imaging Microscopy. The data (counts of 2 - 10µm particles per vial) for the blank 
represent the mean of 48 individual measurements, and for ErA the mean of 11 individual 
lot measurements. The error bars represent ±1SD. The y-axis is presented as a 
logarithmic scale. 
  
 
 
Figure 4. FIM SbVP counts for ErA (particles per vial in the 2 – 10µm size range). The 
results are presented as inter-lot variability for eleven DP lots. Each bar in the inter-lot 
plot represents the mean of four separate reconstituted vials.  Error bars represent ±1SD. 
  
 
 
Figure 5. Comparison of SbVP data (particles per vial in 2 – 10µm range) for 11 ErA DP 
lots using both LO and FIM. FIM data represent the mean of four imaged vials. The 
variability in FIM data (±1SD error bars) are also shown. 
  
 
 
Figure 6. Typical ErA FIM particle size distribution in the size range 2 – 10µm. The 
histogram bars show the number of particles in each one-micron size interval. The curve 
represents the cumulative percentage of particles less than or equal to the ESD at that point 
(eg at 6µm approximately 90% of the particles in the 2 – 10µm size range are at this size 
or smaller). 
  
 
 
Figure 7.  Images of typical ErA SbVP generated by FIM.  The ESD as determined by the 
FIM software is indicated next to each set of images. The bar represents 20µm. 
 
Table 1.  Software settings for FIM analyses. 
 
Parameter Value(s) 
 
Particle Segmentation 
Dark Threshold  22.00 
 
Light Threshold 17.00 
Distance to Nearest Neighbor 7µm 
Close Holes 5 iterations 
 
Basic Size Filter 
Diameter (ESD) Min 2.00µm 
 
Max 10000µm 
Advanced Filter None 
AutoImage Frame Rate 20 frames per second 
Flash Duration 16.00µsec 
Camera Gain 0 
Analysis Volume 250µL 
Run Time Approx. 6 minutes 
Table 2. Clinical data showing incidence in allergic reactions for an ErA lot (Target 
Lot) with comparatively higher SbVP content by LO and FIM, compared with 
incidence for all other ErA treatment lots. 
Lot ID 
Allergic 
Reaction 
No Allergic 
Reaction Total 
Allergic 
Reactions as 
% of Total 
Target Lot 15 213 228 6.6% 
Not Target Lot 124 1,016 1,140 10.9% 
Total 139 1,229 1,368 
